Akanda

Akanda Forward P/E

The Forward P/E Ratio of Akanda (AKAN) as of Oct 25, 2026 is -0.04. In the previous year, Forward P/E Ratio was -0.40 — a change of -91.03% (higher).

Forward P/E

-0.04

YoY

-91.03%

Last updated:

Forward P/E Ratio of Akanda is 2025 -0.04 . Forward P/E Ratio of Akanda was 2024 -0.40 . It decreases by -91.03% higher compared to the previous year.

The Akanda Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2019
-0.86 USD
Jan 1, 2020
-0.70 USD
Jan 1, 2021
-0.20 USD
Jan 1, 2022
-0.14 USD
Jan 1, 2023
-0.05 USD
Jan 1, 2024
-0.40 USD
Jan 1, 2025
-0.04 USD
The Akanda Forward P/E history
YEARForward P/EYoY
-0.04-91.03%
-0.40+687.96%
-0.05-63.88%
-0.14-30.25%
-0.20-71.71%
-0.70-17.91%
-0.86—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Akanda Stock analysis

What does Akanda do? Akanda Corp generates revenue through its cultivation, distribution, and corporate segments. The cultivation segment focuses on producing medical cannabis and biomass, while the distribution segment sells products like those from Holigen, a Portugal-based cultivator, manufacturer, and distributor, and CanMart, a UK-based pharmaceutical importer and distributor supplying pharmacies and clinics. Holigen operates a 20,000 square foot indoor facility near Lisbon for high-THC cannabis cultivation. The company’s supply chain includes Cansativa Group, an European medical cannabis importer and distributor, and Cellen Life Sciences Leva Clinic, a UK-based digital pain clinic. Holigen’s products are distributed through Akanda’s network, targeting medical cannabis patients globally. CanMart serves UK pharmacies and clinics, leveraging its pharmaceutical licensing. Cansativa Group and Cellen Life Sciences Leva Clinic are integral to the seed-to-patient supply chain, connecting cultivation with end users. The company monetizes its portfolio by supplying ethically sourced medical cannabis products to patients worldwide through these established brands. Akanda’s revenue streams are derived from the sale of medical cannabis products via Holigen’s cultivation, CanMart’s distribution, and the supply chain involving Cansativa Group and Cellen Life Sciences Leva Clinic. The cultivation segment produces biomass for distribution, while the distribution segment handles sales to healthcare providers and clinics. The corporate segment supports these operations with strategic oversight. Akanda is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Akanda stock

Forward P/E Ratio of Akanda is -0.04 in 2025.

Forward P/E Ratio of Akanda changed from -0.40 to -0.04, representing a -91.03% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Akanda since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Akanda with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Akanda

All Key Metrics — Akanda